This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n5http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n9http://linked.opendata.cz/resource/domain/vavai/subjekt/
n8http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n18http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00023736%3A_____%2F11%3A00009192%21RIV12-MZ0-00023736/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n13http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00023736%3A_____%2F11%3A00009192%21RIV12-MZ0-00023736
rdf:type
n8:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.3109/03630269.2011.578515
dcterms:description
Forty-eight patients with early myelodysplastic syndrome (MDS) without excess of blasts, with average initial serum ferritin levels of 2739.5 μg/L (range 825–11287 μg/L), were treated with deferiprone (L1) in a daily dose of 40–90 mg/kg. Median duration of chelation treatment was 10.9 months (range 4–24 months). Chelation was effective (maintained or decreased iron stores) in 16 out of 22 patients (73%) with serum ferritin levels <2000 μg/L in contrast to only 12 out of 26 patients with serum ferritin levels >2000 μg/L. Combination of L1 with recombinant human erythropoietin (rHuEPO) (30–40 kU/week) resulted in effective chelation in five additional patients with serum ferritin levels >3000 μg/L. Incidence of adverse effects was comparable to thatin thalassemic patients. A decreased number of granulocytes was observed in five (13%) patients and agranulocytosis occurred in two patients (4%). Administration of L1 in a daily dose of at least 75 mg/kg may represent an alternative approach Forty-eight patients with early myelodysplastic syndrome (MDS) without excess of blasts, with average initial serum ferritin levels of 2739.5 μg/L (range 825–11287 μg/L), were treated with deferiprone (L1) in a daily dose of 40–90 mg/kg. Median duration of chelation treatment was 10.9 months (range 4–24 months). Chelation was effective (maintained or decreased iron stores) in 16 out of 22 patients (73%) with serum ferritin levels <2000 μg/L in contrast to only 12 out of 26 patients with serum ferritin levels >2000 μg/L. Combination of L1 with recombinant human erythropoietin (rHuEPO) (30–40 kU/week) resulted in effective chelation in five additional patients with serum ferritin levels >3000 μg/L. Incidence of adverse effects was comparable to thatin thalassemic patients. A decreased number of granulocytes was observed in five (13%) patients and agranulocytosis occurred in two patients (4%). Administration of L1 in a daily dose of at least 75 mg/kg may represent an alternative approach
dcterms:title
Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome
skos:prefLabel
Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome
skos:notation
RIV/00023736:_____/11:00009192!RIV12-MZ0-00023736
n8:predkladatel
n9:ico%3A00023736
n4:aktivita
n7:I n7:N
n4:aktivity
I, N
n4:cisloPeriodika
3
n4:dodaniDat
n13:2012
n4:domaciTvurceVysledku
n5:4787552
n4:druhVysledku
n16:J
n4:duvernostUdaju
n12:S
n4:entitaPredkladatele
n10:predkladatel
n4:idSjednocenehoVysledku
196700
n4:idVysledku
RIV/00023736:_____/11:00009192
n4:jazykVysledku
n17:eng
n4:klicovaSlova
deferiprone (L1); myelodysplastic syndrome; iron overload
n4:klicoveSlovo
n15:myelodysplastic%20syndrome n15:iron%20overload n15:deferiprone%20%28L1%29
n4:kodStatuVydavatele
US - Spojené státy americké
n4:kontrolniKodProRIV
[EAF6F3DD075F]
n4:nazevZdroje
Hemoglobin
n4:obor
n19:FD
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
7
n4:rokUplatneniVysledku
n13:2011
n4:svazekPeriodika
35
n4:tvurceVysledku
Neuwirtová, R. Čermák, Jaroslav Šišková, M. Jonášová, A. Walterová, L. Hochová, I. Vondráková, J.
n4:wos
000290797500005
s:issn
0363-0269
s:numberOfPages
11
n18:doi
10.3109/03630269.2011.578515